[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Nadir Mahmood Biography and Net Worth

Insider of Nkarta

Dr. Mahmood was named Chief Financial and Business Officer in 2020. He joined Nkarta in 2018 to lead corporate and business development activities. Prior to that, he headed corporate development at Second Genome where he was responsible for establishing strategy and partnerships across the company’s portfolio of programs and oversaw all intellectual property matters. Earlier in his career, Dr. Mahmood was Staff Scientist at Kythera Biopharmaceuticals (acquired by Allergan), overseeing preclinical research for the company’s lead molecule, Kybella®. He has also worked in equity research at Goldman Sachs and consulted for early stage companies in the life sciences and clean energy sectors.

He has a bachelor’s degree in Biochemistry from the University of Texas at Austin and received his doctoral degree from the Department of Pharmacology at the University of Texas Southwestern Medical Center at Dallas. Dr. Mahmood completed postdoctoral research at the Scripps Research Institute in La Jolla, CA.

How do I contact Nadir Mahmood?: The corporate mailing address for Dr. Mahmood and other Nkarta executives is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. Nkarta can also be reached via phone at 925-407-1049 and via email at [email protected]. Learn More on Nadir Mahmood's contact information.
Has Nadir Mahmood been buying or selling shares of Nkarta?: Nadir Mahmood has not been actively trading shares of Nkarta in the last ninety days. Most recently, Nadir Mahmood sold 6,500 shares of the business's stock in a transaction on Thursday, July 1st. The shares were sold at an average price of $31.71, for a transaction totalling $206,115.00. Learn More on Nadir Mahmood's trading history.
Who are Nkarta's active insiders?: Nkarta's insider roster includes Ralph Brandenberger (Insider), Paul Hastings (CEO), Nadir Mahmood (Insider), and Kanya Rajangam (Insider). Learn More on Nkarta's active insiders.
Are insiders buying or selling shares of Nkarta?: During the last year, Nkarta insiders bought shares 1 times. They purchased a total of 2,000,000 shares worth more than $20,000,000.00. During the last year, insiders at the sold shares 4 times. They sold a total of 20,788 shares worth more than $192,680.26. The most recent insider tranaction occured on July, 16th when insider Alicia J Hager sold 3,396 shares worth more than $27,168.00. Insiders at Nkarta own 8.7% of the company. Learn More about insider trades at Nkarta.
Information on this page was last updated on 7/16/2024.

Nadir Mahmood Insider Trading History at Nkarta

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
7/1/2021	Sell	6,500	$31.71	$206,115.00
5/10/2021	Sell	3,000	$27.16	$81,480.00
4/1/2021	Sell	3,500	$32.70	$114,450.00
1/25/2021	Sell	5,500	$48.57	$267,135.00

Nadir Mahmood Buying and Selling Activity at Nkarta

Nkarta Company Overview

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Today's Range

Now: $2.45

$2.40

$2.50

50 Day Range

MA: $3.79

$2.44

$5.65

2 Week Range

Now: $2.45

$2.38

$16.24

Volume

1,936,972 shs

Average Volume

1,120,529 shs

Market Capitalization

$172.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86